ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical data have shown that the combination of PON + ASC was preferable for treating a patient with CML; for instance, adding 50 nM ASC can effectively reduce the IC50 of PON by 5.6-fold for BCR-ABL with T315M mutation and more than 7-fold for BCR-ABL with Y253/T315I mutation [44,45].